aTyr Pharma aligns with FDA on Phase 3 efzofitimod trial in pulmonary sarcoidosis
aTyr Pharma aligned with the FDA on a Phase 3 efzofitimod trial in chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. Study-related activities are expected to start in Q4 2026 as the company prepares U.S. and European regulatory submissions. Trial will test whether efzofitimod can improve lung fu